Landmark study identifies large number of new proteins implicated in Huntington’s disease
Contact: Kris Rebillot
krebillot@buckinstitute.org
415-209-2260
Buck Institute for Age Research
Buck Institute faculty leads large scale screening of protein interactions to identify drug targets for possible treatment of incurable disease
Researchers from four organizations have identified more than 200 new proteins that bind to normal and mutant forms of the protein that causes Huntington’s disease (HD). HD is a fatal inherited disease that affects 30,000 Americans annually by laying waste to their nervous system. The research was led by Buck Institute faculty member Robert E. Hughes, PhD. Results of the study, which may facilitate the discovery of an effective treatment for HD, will be published in the May 11 edition of PLoS Genetics, an online, open-source journal, enabling scientists from around the world to take advantage of the findings immediately.
The work, which involved high-tech screening of the human genome and proteome, was unprecedented both in terms of its scale and in the way the protein interactions were validated in a genetic model of the disease. By conducting additional experiments in fruit flies genetically altered to express features of human HD, scientists showed that changing the expression of these interacting proteins affected the degree of damage seen in the fly neurons. This indicates that a significant number of the proteins might be potential drug targets for HD.
Now that researchers have discovered the interacting proteins using human libraries and human protein extracts and tested them in the fly, Hughes says the next step is to bring the research back into the mammalian world. The new genes and proteins discovered in this study are being screened and analyzed in cultured mammalian cells; the ones that show activity in ongoing experiments will be tested in mouse models of HD.
“Here at the Buck Institute, we’re going to be focusing on a few dozen proteins,” said Hughes. “Effective follow-up on any target protein depends, in large part, on how much expertise a scientist has with that target. We are hoping that researchers will look at this study and that those with specific expertise in a particular protein will move forward with their own inquiries.”
The work was supported by HD advocacy organizations. “We are very excited about this significant discovery,” said Allan Tobin, PhD, Senior Scientific Advisor to the High Q Foundation and CHDI, Inc. “This work helps define and refine possible therapeutic targets for a disease that lacks thorough understanding.” Tobin added, “We are pleased this study is being published in an open-access journal, which makes it easier for scientists at other organizations to get to work on following up on this landmark discovery.” Traditional peer-reviewed journals usually require scientists to pay a fee to access study results.
Tobin added that the need for further scientific inquiry is urgent. There is currently no effective treatment or cure for HD, which is typically characterized by involuntary movements and dementia. The disease slowly diminishes a person’s ability to move, think and communicate. Those affected eventually become totally dependent on others for their care and usually die from complications such as choking, heart failure or infection. The disease is hereditary; each child of a person with HD has a 50/50 chance of inheriting the fatal gene. Approximately 200,000 Americans are believed to be at risk of developing HD, a disease that affects as many people as hemophilia, cystic fibrosis or muscular dystrophy. The symptoms of HD typically begin to appear in mid-life, although the progression of the disease varies among individuals and within the same family.
###
Joining Hughes as co-authors of the paper are Buck Institute scientists Cameron Torcassi, and Lisa Ellerby; along with Eliana Romano and Juan Botas from the Baylor College of Medicine in Houston; Andrew Strand, and James Olson from the Fred Hutchinson Cancer Research Center in Seattle; and Linda Kaltenbach, Sudhir Sahasrabudhe, Cornelia Kurschner, and John M. Peltier of Prolexys Pharmaceuticals in Salt Lake City. The work was supported by grants from the HighQ Foundation, CCHI Inc, the Hereditary Disease Foundation and National Institutes of Health.
The Buck Institute is an independent non-profit organization dedicated to extending the healthspan, the healthy years of each individual’s life. The National Institute of Aging designated the Buck a Nathan Shock Center of Excellence in the Biology of Aging, one of just five centers in the country. Buck Institute scientists work in an innovative, interdisciplinary setting to understand the mechanisms of aging and to discover new ways of detecting, preventing and treating age-related diseases such as Alzheimer’s and Parkinson’s disease, cancer, stroke, and arthritis. Collaborative research at the Institute is supported by genomics, proteomics and bioinformatics technology. For more information: http://www.buckinstitute.org.
Global Health Vision
-
Archives
- January 2009 (1)
- December 2007 (2)
- November 2007 (1)
- October 2007 (11)
- September 2007 (17)
- August 2007 (24)
- July 2007 (25)
- June 2007 (21)
- May 2007 (32)
-
Categories
- 25-hydroxyvitamin D
- Acetaminophen and Caffeine
- Acinetobacter calcoaceticus-baumannii complex
- acute lymphoblastic leukemia
- Alberta
- Alzheimers
- American Academy of Neurology
- American Association for Cancer Research
- American Chemical Society
- American College of Cardiology
- American Heart Association
- American Journal of Clinical Nutrition
- American Journal of Public Health
- American Legacy Foundation
- Ancestral Heritage
- Antibodies
- Archives of Neurology
- Arthritis
- Arthritis & Rheumatism
- ASD
- Autism
- Autism Spectrum Disorders
- Autoimmune Diseases
- B. Rappaport Faculty of Medicine at Technion in Haifa
- Baltimore
- Barcelona
- Bethesda
- Biological Sciences
- Blackwell Publishing Ltd.
- Bone Demineralisation
- Bone Diseases
- Boston
- British Medical Journal
- Brooke Army Medical Center
- Buck Institute
- Calabria Regional Health Department
- Calgary
- Canada
- Canadian Institutes of Health Research
- Cancer
- Cancer Biology
- Cancer Biology and Therapy
- Cancer Information In Spanish
- Cardiovascular Disease
- Catalan Institute of Oncology in Spain
- Chemotherapy
- Childhood Lukemia
- Childhood Nutrition
- Children's Hospital of Philadelphia
- Children’s Cancer Institute Australia
- Children’s Hospital
- Children’s Hospital of Philadelphia
- Childrens Hospital Los Angeles
- Chile
- Chromosome 17
- Chromosome 8
- Chronic
- Chronic Multisymptom Illnesses
- Chronic Stress
- Chronic Stress and Obesity
- CHS National Cancer Control Center and Technion
- CHS National Israeli Cancer Control Center
- Clinical Applications
- Clinical Trials
- Cocaine
- College of Medicine in Houston
- Complex Chronic Conditions
- COPD
- Cornell University
- Cytochrome b5
- Cytochrome P450
- Dementia
- Depression
- Diabetes
- DNA
- Drug Abuse
- Drug-Resistant
- Duke University Medical Center
- Electronic Health Records
- Emergency Preparedness
- Emergency Room
- Emory Genetics Laboratory
- Emory University
- End Of Life Care
- Enzymes
- Epidemiology
- Epilepsy
- European Cancer Conference
- European Journal of Cancer Care
- European League Against Rheumatism
- European Science Foundation
- FDA Warnings
- FEMA
- Fibromyalgia
- Fibromyalgia News
- FMS Global News
- Folic Acid
- Fort Sam Houston
- Fox Chase Cancer Center
- France
- Fred Hutchinson Cancer Research Center
- Garvan Institute of Medical Research
- General Psychiatry
- Genes
- Genetic
- Genetic Link
- Genetic Marker C allele of rs10505477
- Genetics
- Genome
- Genomic
- Germany
- Global
- Global Health Vision
- Global News
- Health
- Health Canada
- Health Information Technology
- Heart Disease
- Hebrew University of Jerusalem
- Hemorrhagic Stroke
- Historical Medicine
- HIV
- Hospital Epidemiology
- Hospital Trauma
- Howard Hughes Medical Institute
- Human Genome
- Hunger
- Huntington's disease
- hypertension
- Imperial College London
- Interactive Autism Network
- Inuit children
- Iraq
- Irvine
- Irving Weinstein Foundation
- Italy
- JAMA
- JAMA/Archives journals
- Japan
- Japanese Society for the Promotion of Science
- Johns Hopkins University
- Joint Health Research Program
- journal BBA Biomembranes
- journal Cell
- journal Nature Genetics
- Journal of Clinical Investigation
- Journal of Experimental Social Psychology
- Journal of the American College of Surgeons
- Journal of Theoretical Biology
- Juvenile Diabetes
- Karolinska Institute in Stockholm
- Kennedy Krieger Institute
- Kyowakai Hospital
- Lamezia Terme
- Leukemia
- LKB1
- London
- London UK Feed
- Lung Cancer
- Lupus
- Malaria
- Massachusetts General Hospital
- Mayo Clinic
- McMaster University
- MD
- Medical History
- Medical Insurance
- Medical Journals
- Mitochondrial Diseases
- Molecular Biology
- Molecular Epidemiology
- MS
- Multiple Sclerosis
- Muscular Dystrophy
- Music Video Of The Day
- Music Video Pick Of The Day
- Nanobiotechnology
- National Cancer Institute
- National Institute on Aging
- National Institutes of Health
- Nature
- Nature Genetics
- Neurodegenerative Diseases
- Neurology
- Neuropeptide Y
- New England Journal of Medicine
- New York University
- Newfoundland
- News
- News Australia
- News Canada
- News France
- News Germany
- News Israel
- News Italy
- News Jerusalem
- News Switzerland
- News UK
- News US
- News USA
- NIH
- non-Hodgkin's lymphoma
- Norepinephrine
- Northwestern University
- Nova Scotia
- Nunavut
- Nutritional Anthropology
- Oak Ridge National Laboratory
- Obesity
- Occupational Health
- omega-3 fatty acids
- Oncology
- Orthopaedic Research Society
- Osaka
- Osteoarthritis
- Ottawa
- Ottawa City Feed
- Oxford University
- Pain
- Pain Management
- Palliative Care
- Parkinson Society of Canada
- Parkinson's
- Pediatric Palliative Care
- Pennsylvania
- Peutz-Jeghers syndrome
- Pharmacology and Neuroscience
- Pick's Disease
- Pre/Post Natal Care
- Preventive Medicine
- Prince Edward Island
- Progranulin
- Protein Growth Factor
- Proteins
- Proteome
- PTSD
- Public Health
- Quebec
- Research
- Research Australia
- Rheumatoid Arthritis
- Rickets
- RSS
- RSS Feed
- Rush Alzheimer’s Disease Center
- Science
- Seattle Washington
- SLE
- Slovakia
- Spain
- Spanish
- Spina Bifida
- Spinal Cord Injuries
- St. Elmos Fire
- St. Jude Children's Research Hospital
- Statin Drugs
- Stem Cells
- Stroke
- Sydney Children’s Hospital
- Systemic Lupus Erythematosus
- TB
- Temple University
- Tendons
- The American Academy of Neurology
- the Israel Institute of Technology
- Toronto
- Toronto City Feed
- trauma-associated and hospital-acquired infection
- Tuberculosis
- Type 1 Diabetes
- Type 2 Diabetes
- UCLA
- UCSD
- UK
- Uncategorized
- Unemployment
- Université Laval
- University College London
- University Hospital in Geneva
- University New South Wales
- University of Bern
- University of Calgary
- University of California
- University of Chicago
- University of Chicago Press Journals
- University of Florida
- University of Granada
- University of Manchester
- University of Michigan
- University of Missouri
- University of North Carolina
- University of North Texas
- University of Nottingham
- University of Oregon
- University of Pennsylvania School of Medicine
- University of Pittsburgh
- University of Rochester
- University of Toronto
- US
- US Army soldiers in Iraq
- US Military Hospitals
- USC
- UT Southwestern Medical Center
- Virginia
- Viruses
- Vitamin D
- W. Garfield Weston Fellows
- Wake Forest University Baptist Medical Center
- WASHINGTON
- Washington DC
- Washington DC City Feed
- Washington University
- Weather Anomolies
- Weill Medical College
- Wellcome Trust
- World Health Organisation
- World News
- Yale University
-
RSS
Entries RSS
Comments RSS